Osimertinib or platinum-pemetrexed in EGFR T790M-Positive lung cancer

New England Journal of Medicine

Volumn 376, Issue 7, 2017, Pages 629-640

  Mok, T S ^a   Wu, Y L ^b   Ahn, M J ^d   Garassino, M C ^f   Kim, H R ^e   Ramalingam, S S ^g   Shepherd, F A ^h   He, Y ^c   Akamatsu, H ⁱ   Theelen, W S M E ^j   Lee, C K ^k   Sebastian, M ^l   Templeton, A ^m   Mann, H ^m   Marotti, M ^m   Ghiorghiu, S ^m   Papadimitrakopoulou, V A ⁿ  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

^d Sungkyunkwan University School of Medicine   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h PRINCESS MARGARET HOSPITAL   (Canada)

ⁱ WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^j NETHERLANDS CANCER INSTITUTE   (Netherlands)

^k ST GEORGE HOSPITAL   (Australia)

^l UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^m ASTRAZENECA   (United Kingdom)

ⁿ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; METHIONINE; OSIMERTINIB; PEMETREXED; PLATINUM COMPLEX; TYROSINE; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; PLATINUM;

ADULT; AMINO ACID SUBSTITUTION; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BACKACHE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; COMPARATIVE EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DRUG SAFETY; DRY SKIN; DYSPNEA; EGFR GENE; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OPEN STUDY; PARONYCHIA; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING; AGED; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; MUTATION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PEMETREXED; PIPERAZINES; PLATINUM; RECEPTOR, EPIDERMAL GROWTH FACTOR; YOUNG ADULT;

EID: 85013382512     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1612674     Document Type: Article

References (28)

1. Masters GA, Temin S, Azzoli CG, et al. Systemic therapy for Stage IV non-smallcell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol 2015; 33: 3488-515.
2. Novello S, Barlesi F, Califano R, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27: Suppl5: v1-v27.
3. Tan DS, Yom SS, Tsao MS, et al. The International Association for the Study of Lung Cancer consensus statement on optimizing management of EGFR mutationpositive non-small cell lung cancer: status in 2016. J Thorac Oncol 2016; 11: 946-63.
4. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: NSCLC (version 3.2017). 2016 (http://www.nccn.org/professionals/physician-gls/pdf/nscl.pdf).
5. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non- small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-8.
6. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-8.
7. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-42.
8. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-46.
9. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31: 3327-34.
10. Wu YL, Zhou C, Liam CK, et al. Firstline erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation- positive non-small-cell lung cancer: Analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol 2015; 26: 1883-9.
11. Wu Y-L, Zhou C, Hu C-P, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): An open-label, randomised phase 3 trial. Lancet Oncol 2014; 15: 213-22.
12. Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-57.
13. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-92.
14. Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013; 19: 2240-7.
15. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3: 75ra26.
16. Oxnard GR, Arcila ME, Sima CS, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011; 17: 1616-22.
17. Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008; 105: 2070-5.
18. Sos ML, Rode HB, Heynck S, et al. Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Res 2010; 70: 868-74.
19. Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014; 4: 1046-61.
20. Ballard P, Yates JW, Yang Z, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res 2016; 22: 5130-40.
21. Yang JC-H, Kim D-W, Kim S-W, et al. Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from nonsmall cell lung cancer (NSCLC): updated results from BLOOM, a phase I study. J Clin Oncol 2016; 34: Suppl:9002. abstract.
22. Jänne PA, Yang JC-H, Kim D-W, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015; 372: 1689-99.
23. Yang J, Ramalingam SS, Jänne PA, Cantarini M, Mitsudomi T. LBA2-PR: Osimertinib (AZD9291) in pre-Treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results. J Thorac Oncol 2016; 11: Suppl: S152-S153.
24. FDA approves new pill to treat certain patients with non-small cell lung cancer. Press release of the Food and Drug Administration, November 13, 2015 (http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm472525.htm).
25. Soria J, Kim S, Wu Y, et al. Gefitinib/chemotherapy vs chemotherapy in EGFR mutation-positive NSCLC resistant to firstline gefitinib: IMPRESS T790M subgroup analysis. J Thorac Oncol 2015; 10: Suppl: S207-S208.
26. Oxnard GR, Thress KS, Alden RS, et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-smallcell lung cancer. J Clin Oncol 2016; 34: 3375-82.
27. Jenkins S, Yang J, Ramalingam S, et al. 134O-PR: Plasma ctDNA analysis for detection of EGFR T790M mutation in patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (aNSCLC). J Thorac Oncol 2016; 11: 4Suppl: S153-S154.
28. Soria JC, Wu YL, Nakagawa K, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation- positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): A phase 3 randomised trial. Lancet Oncol 2015; 16: 990-8.